Nanjing Chia-tai Tianqing Pharmaceutical
Clinical trials sponsored by Nanjing Chia-tai Tianqing Pharmaceutical, explained in plain language.
-
New pill could help PNH patients avoid transfusions
Disease control Not yet recruitingThis study tests a new oral medication, NTQ5082, for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that destroys red blood cells. The trial will include about 78 adults who have not received prior complement inhibitor therapy. The main goal is to se…
Phase: PHASE3 • Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical • Aim: Disease control
Last updated May 17, 2026 09:17 UTC
-
New drug aims to reduce eye bulging in thyroid disease
Disease control Not yet recruitingThis study tests a new drug called NTB003 for people with thyroid eye disease, a condition that can cause bulging eyes and discomfort. About 74 adults aged 18-75 with active disease will receive the drug to see if it safely reduces eye bulging and inflammation. The main goal is t…
Phase: PHASE1, PHASE2 • Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical • Aim: Disease control
Last updated May 17, 2026 09:11 UTC
-
New hope for Hard-to-Treat breast cancer: targeted combo trial launches
Disease control Not yet recruitingThis phase 3 trial tests whether adding the experimental drug NTQ1062 to standard hormone therapy (fulvestrant) can slow or stop cancer growth in people with advanced HR+/HER2- breast cancer that has specific genetic changes (PIK3CA/AKT1/PTEN). About 210 adults whose cancer worse…
Phase: PHASE3 • Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical • Aim: Disease control
Last updated May 15, 2026 11:53 UTC